A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology populationJeanine Flanigan, G.H. Lyman, Edward Li et al.|Journal of Medical Economics|2025Cited by 1
Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal OsteoporosisJeanine Flanigan, GH Lyman, Sarah Kane et al.|PharmacoEconomics - Open|2026Cited by 1
HSR24-146: Chemotherapy-Induced Febrile Neutropenia (FN) in the US: Healthcare Resource Utilization (HCRU) and CostsEdward Li, Chi‐Chang Chen, Jeanine Flanigan et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 0